Protocol Ledger

NCT07161258 · Phase II · RECRUITING

A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)

Interventional Phase II clinical trial protocol NCT07161258 sponsored by Roche / Genentech in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-10-06 Enrollment: 12 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07161258
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)12 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07161258
Protocol FieldVerified Registry Value
NCT IdentifierNCT07161258
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment12 participants (ESTIMATED)
Registered Start Date2025-10-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07161258
Hospital Research SiteLocationSite Profile
Uniwersyteckie Centrum KliniczneGdansk, PolandOpen Hospital Dossier ->
Hospital Universitario de La PrincesaMadrid, SpainOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI